Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 15Etoposide 13atezolizumab 9Topotecan 8durvalumab 7Specimen Handling 7PM 01183 6Cisplatin 5pembrolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 3Biopsy 3berzosertib 2Nivolumab 2Fulvestrant 2Drug Therapy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tazemetostat 1palbociclib 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1budigalimab 1arginine decarboxylase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × BAY 1895344 × 30 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡